U.S. Women's Health Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

U.S. Women's Health Market Trends and Insights

Rising Demand for Noninvasive and In-Office Women's Health Procedures

The United States women's health market is increasingly adopting procedures in lower-acuity settings. In April 2026, Femasys introduced FemaSeed Complete, enabling OB-GYNs to perform first-line inseminations and in-office sperm preparations, reducing reliance on external labs. This innovation simplifies fertility care access and lowers patient costs. Additionally, the approval of a new Category III CPT code for FemaSeed intratubal insemination in early 2026 strengthens reimbursement pathways, accelerating treatment adoption and patient participation.

Expanding Clinical Recognition of Menopause as a Treatable Condition

Menopause care is becoming a mainstream focus in the United States women's health market, driving increased demand. The FDA approved elinzanetant in October 2025, expanding non-hormonal treatment options for menopause-related hot flashes. In February 2026, the FDA removed boxed warnings from six hormone therapy products, addressing long-standing prescribing concerns. These developments are fostering evidence-based care and encouraging more women to seek diagnosis and treatment during midlife.^{[1]Food and Drug Administration, “FDA Approves Labeling Changes to Menopausal Hormone Therapy Products,” FDA, fda.gov}

Higher Utilization of Fertility Diagnostics and Assisted Reproductive Technologies

Fertility care is gaining prominence in the United States women's health market. A 2025 NCHS report revealed that 13.7% of women aged 20 to 49 used fertility services, with 6.9% undergoing infertility testing, highlighting strong demand.^{[2]National Center for Health Statistics, “Use of Fertility Services in the United States,” CDC Data Brief 542, cdc.gov} In May 2026, the U.S. Department of Labor proposed a rule capping fertility benefits at USD 120,000, simplifying employer-sponsored coverage. Progyny reported serving over 600 employers and 7.2 million covered lives in 2026, improving access to fertility diagnostics and treatments.^{[3]U.S. Department of Labor, “Excepted Benefits Relating to Certain Fertility and Reproductive Health Benefits,” U.S. Department of Labor, dol.gov}

Payor and Employer Interest in Women's Health Benefits

Employer and payor initiatives are strengthening the United States women's health market. The Department of Labor's proposed rule on fertility benefits provides employers with a clearer framework for coverage. In April 2026, Progyny launched Progyny Select, a fully insured supplemental fertility plan for small employers, addressing affordability challenges. These efforts are expanding employer-linked coverage, creating a stable reimbursement base and driving treatment uptake across fertility and related services.

Persistent Underdiagnosis and Late Treatment Initiation

Underdiagnosis limits the United States women's health market from converting clinical needs into treatment volumes. Polycystic ovary syndrome affects 6% to 12% of women of reproductive age, yet many remain undiagnosed for extended periods. Endometriosis in the United States faces an average diagnostic delay of 4.4 years, leading to economic burdens as care often begins after symptoms worsen. Uterine fibroids and endometriosis remain underdiagnosed across care settings, creating a gap between prevalence and documented treatment. Late diagnoses reduce early-stage pharmaceutical use and shift patients toward complex, less scalable interventions.

Coverage Friction for Long-Acting Contraception and Fertility Treatments

Coverage gaps slow access in the United States women's health market. Ten states that have not adopted Medicaid expansion leave 1.4 million eligible individuals without government-sponsored insurance, limiting access to contraception and preventive care. Twenty percent of uninsured women of reproductive age stopped using contraception due to costs, compared to 5% of Medicaid-covered women. Self-funded employer plans, exempt from state IVF mandates under ERISA, create uneven access even in states with coverage requirements. These gaps hinder uptake in high-need groups and slow the market's ability to convert demand into revenue.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Offering: Pharmaceuticals Anchor the Market While Digital Health Reshapes Delivery

In 2025, pharmaceuticals accounted for 45.12% of the United States women's health market, driven by their role in managing contraception, menopause, endometriosis, and PCOS. Prescription therapies remain the primary treatment for high-volume conditions. The FDA's approval of elinzanetant in October 2025 expanded non-hormonal menopause treatment options. Organon reported a 16% decline in women's health revenue in Q1 2026, emphasizing the need for portfolio renewal alongside scale.

Digital health solutions are projected to grow at a 7.25% CAGR through 2031, making them the fastest-growing segment. Maven expanded its virtual clinic in May 2026, integrating GLP-1 care, hormone therapy, and over 30 women's health specialties. Diagnostics and device-led offerings, such as the Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, are enhancing access to less invasive care pathways.

By Application: Contraception Leads, but Menopause and Specialty Conditions Gain Faster Momentum

Contraception and family planning represented 36.76% of the United States women's health market in 2025, reflecting their broad role across retail, provider, and public coverage channels. This segment benefits from recurring prescriptions, long-acting products, and preventive care, supported by digital platforms for consultations and renewals.

Menopause management is projected to grow at a 6.56% CAGR through 2031, driven by new non-hormonal treatments and updated hormone therapy labels. Endometriosis and PCOS remain key growth areas due to high disease burden and unmet needs, with diagnosis improvements expected to boost medication use and specialist referrals.

By Care Setting: Hospitals Retain Core Volume While Virtual Channels Expand Faster

Hospitals held 40.67% of the United States women's health market in 2025, reflecting their role in complex procedures and high-acuity reproductive services. Their importance lies in procedural intensity and multidisciplinary care, which cannot easily shift to lower-cost settings.

Telehealth and virtual platforms are projected to grow at a 7.35% CAGR through 2031. Twentyeight Health launched a nationwide virtual clinic in April 2026, partnering with over 100 insurers to reach approximately 16 million women. Femasys is enabling first-line fertility treatments in OB-GYN offices, redistributing routine care while maintaining hospital relevance for complex cases.

By Age Group: Reproductive-Age Women Hold the Largest Base While Postmenopausal Care Drives Growth

Reproductive-age women accounted for 51.34% of the United States women's health market in 2025, driven by frequent care needs such as contraception, fertility, prenatal services, and diagnostic testing. This segment benefits from recurring touchpoints that ensure steady demand.

Postmenopausal women are projected to grow at a 6.92% CAGR through 2031, supported by increased clinical acceptance of menopause treatments and new therapeutic options like elinzanetant. This growth highlights the rising importance of midlife and later-life care in the market.

By Distribution Channel: Retail Pharmacies Lead, but Online and DTC Access Is Growing Faster

Retail pharmacies held a 45.78% share of the United States women's health market in 2025, supported by prescription refill continuity, insurance-linked access, and geographic reach. They remain critical for long-term therapies requiring adherence.

Online pharmacies and direct-to-consumer channels are projected to grow at a 7.66% CAGR through 2031. Twentyeight Health and Maven Clinic are streamlining consultation, prescribing, and delivery, while employer-linked channels are driving scalability and convenience, challenging traditional distribution models to enhance service and efficiency.

Geography Analysis

The women's health market in the United States operates nationally but varies significantly by state due to differences in coverage rules, specialist availability, and delivery models. States with stronger insurance support for family planning and fertility services see higher utilization rates due to reduced coverage barriers and clearer referral pathways. Regions with established provider networks for menopause care, fertility treatments, and diagnostics benefit more quickly. Major metropolitan areas lead in adoption due to specialist density, employer coverage, and faster rollout of clinical services, making access more about efficiency than population size.

The South and Midwest face the most challenges in the United States women's health market due to coverage gaps and provider shortages. Ten non-expansion states leave 1.4 million eligible individuals without government-sponsored insurance, creating concentrated access risks. In 2025, 20% of uninsured women of reproductive age stopped using contraception due to cost, highlighting financial barriers. Virtual care is critical in these regions, reducing reliance on local specialists. Twentyeight Health addresses these gaps by providing nationwide access to approximately 16 million women, including Medicaid members.

Large commercial states dominate the upper tier of the United States women's health market due to advanced employer-sponsored benefits. In 2026, Progyny served over 600 employer clients and approximately 7.2 million covered lives, reflecting concentrated demand in major employment hubs. The market operates through a mix of state policies, employer benefit designs, and provider availability, favoring platforms capable of managing multi-state compliance while ensuring consistent care experiences across locations.